Uncertainties in the Pharmacotherapy of Parkinson’s Disease and How to Solve Them

作者
P. W. Overstall,Carl E Clarke
出处
期刊:Gerontology [Karger Publishers]
卷期号:48 (1): 30-33 被引量:5
标识
DOI:10.1159/000048921
摘要

The causative relationship between levodopa and the long-term motor complications of therapy, along with the possibility that levodopa may be toxic to dopaminergic neurones in vivo, has led to a move away from its use in early Parkinson's disease. Alternatives such as amantadine and the anticholinergics suffer from poor efficacy in comparison and a high side effect profile. Selegiline is probably less effective than levodopa and the issue of its safety versus neuroprotective properties remains unresolved. Long-term trials with the old and newer dopamine agonists as monotherapy have shown that as a class they can delay the development of dyskinesia and probably response fluctuations. However, major uncertainties remain about their use as monotherapy in all patients instead of levodopa. No data on their effect on quality of life and health care costs are available. Most of the trials were heavily biased towards younger patients with Parkinson's disease, so little data in the elderly are available. In later disease when patients have already developed motor complications on levodopa, the choice rests between adjuvant therapy with a dopamine agonist, a catechol-O-methyltransferase inhibitor (COMT; e.g. entacapone), and a monoamine oxidase B inhibitor (MAO B; e.g. selegiline). Trials with the former two classes have confirmed that they can reduce 'off' time, reduce levodopa dose, and improve motor impairments and disabilities with acceptable increases in adverse events including dyskinesia. Trials with selegiline as adjuvant therapy were less rigorous but it can allow a reduction in levodopa dose and motor impairments. No studies have compared these three classes of drug as adjuvant therapy so there is no evidence on which to base rational decisions in this type of patient. A large pragmatic trial which includes older patients is needed to clarify which treatment is best for different stages of the disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
向分公司完成签到,获得积分20
刚刚
势不可挡发布了新的文献求助10
刚刚
所所的应助被業業采纳,获得10
1秒前
zz完成签到,获得积分10
1秒前
长安望星河完成签到,获得积分10
2秒前
liu完成签到,获得积分10
2秒前
2秒前
直率翠绿发布了新的文献求助10
2秒前
2秒前
科研通AI6.3的应助被DW采纳,获得10
4秒前
Eric的应助被长安望星河采纳,获得10
4秒前
魏伯安发布了新的文献求助10
5秒前
LuXiaoyu的应助被艾格采纳,获得10
7秒前
华仔的应助被虞山小王子采纳,获得10
7秒前
mumuder完成签到 ,获得积分10
7秒前
8秒前
wdlc完成签到,获得积分10
9秒前
10秒前
罐装发布了新的文献求助10
11秒前
shang完成签到,获得积分10
11秒前
12秒前
丘比特的应助被风中的嘉熙采纳,获得10
12秒前
yy发布了新的文献求助10
15秒前
领导范儿的应助被DW采纳,获得30
15秒前
元吉的应助被shang采纳,获得10
15秒前
李健的应助被TFauthor采纳,获得10
16秒前
16秒前
辕YUAN完成签到,获得积分10
17秒前
quazer完成签到 ,获得积分10
17秒前
17秒前
18秒前
Ava的应助被wang采纳,获得10
18秒前
小九九发布了新的文献求助10
19秒前
20秒前
魏伯安完成签到,获得积分10
20秒前
20秒前
aq发布了新的文献求助10
20秒前
21秒前
CAO发布了新的文献求助10
21秒前
余治霆完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188249
求助须知:如何正确求助?哪些是违规求助? 9576071
关于积分的说明 21845183
捐赠科研通 7786256
什么是DOI,文献DOI怎么找? 3435261
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482169